Redeye gives a short comment on the news that Saniona’s partner Medix will file a final version of T...
After the recent rights issue, Ascelia has SEK 75.
Redeye takes a positive stance on Teneo AI raising SEK60m from a directed share issue.
We expect two more quarters before a return to growth '25e-'26e EBIT down 19-7%; 26% CAGR '24-'27e 2...
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a...
Redeye updates on EG7 post Q4-results which were in line with our forecast.
Redeye makes positive estimate adjustments on the back of I-Tech’s record Q4 report delivering y/y g...
Redeye state Gapwaves delivered a strong report with Net sales and EBITDA excl.
Redeye argues that AVTECH has secured double-digit growth following the LATAM Airlines agreement sig...
Redeye remains positive to Bredband2 following a Q4 2024 report in line with forecast.
Strong Q4 driven by Engineered Solutions EBITA up 2% organically, but cancelled out by weaker FX Sha...
Order intake +37% y-o-y on return of one key customer '25-'26e EBIT up 13-6% on higher gross margin ...
Conditions remain stable but unfavourable We cut '25e-'26e sales by 9-8% due to the divestment '25e-...
Minor estimate revisions Tougher order intake comps in Q4 NTM EV/EBIT around 7x What to look for in...
DT already achieved a strong year in terms of profitability, and although earnings growth may no lon...
Consti's net sales in Q4 amounted to EUR 92.3m, slightly above our estimates (Evli est.
Orders recover sharply, +30% y-o-y, and sales beat our est.
EBITA SEK 240m (+2% vs. ABG, +3% vs. IR consensus) We expect cons EBITA to come up by ~1-2% Trading ...
Utvecklingen inom portföljbolagen visar på förbättring, där nu Voi uppnått ett positivt rörelseresul...
Q4: Sales SEK 58m, +129% y-o-y, EBIT margin 29% '25e-'26e sales up 10-12% and EBIT adj.
